FIGURE 5.

(A) Meta-analysis of included studies in terms of Grade 3–4 AEs of PD-1 and PD-L1 inhibitors in patients with advanced melanoma (random effects model). (B) Meta-analysis of included RCTs with an analysis of the rate of Grade 3–4 AEs between PD-1 inhibitors and chemotherapy for patients with advanced melanoma (fixed-effects model). (C) Meta-analysis of included RCTs with an analysis of the most common treatment-related Grade 3–4 AE profiles between PD-1 inhibitors and chemotherapy in patients with advanced melanoma (fixed-effects model).